Target family: Leukotriene receptors (type: gpcr)
Target: OXE receptor

Ligand: S‐Y048 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.699999809265137 pIC50
Reference (Journal): Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys.
Published in: Br J Pharmacol

Ligand: Gue1654 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer.
Published in: Nat Chem Biol

Ligand: 5S-HPETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7 pEC50
Reference (Journal): TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis.
Published in: Biochem Biophys Res Commun

Ligand: 5S-HETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis.
Published in: Biochem Biophys Res Commun

Ligand: 5S-HETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Chemical and biological characterization of oxo-eicosatetraenoic acids.
Published in: Biochim Biophys Acta

Ligand: 5S-HETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Stimulation of human neutrophils by 5-oxo-6,8,11,14-eicosatetraenoic acid by a mechanism independent of the leukotriene B4 receptor.
Published in: J Biol Chem

Ligand: 5-oxo-ODE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8 pEC50
Reference (Journal): Human neutrophils convert the sebum-derived polyunsaturated fatty acid Sebaleic acid to a potent granulocyte chemoattractant.
Published in: J Biol Chem

Ligand: 5-oxo-ETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): 5-Oxo-eicosanoids are potent eosinophil chemotactic factors. Functional characterization and structural requirements.
Published in: J Biol Chem

Ligand: 5-oxo-ETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Metabolism of 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid and other 5(S)-hydroxyeicosanoids by a specific dehydrogenase in human polymorphonuclear leukocytes.
Published in: J Biol Chem

Ligand: 5-oxo-ETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): 5-Oxo-ETE and the OXE receptor.
Published in: Prostaglandins Other Lipid Mediat

Ligand: 5-oxo-ETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Structural requirements for activation of the 5-oxo-6E,8Z, 11Z,14Z-eicosatetraenoic acid (5-oxo-ETE) receptor: identification of a mead acid metabolite with potent agonist activity.
Published in: J Pharmacol Exp Ther

Ligand: 5-oxo-ETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Receptors for the 5-oxo class of eicosanoids in neutrophils.
Published in: J Biol Chem

Ligand: 5-oxo-C20:3 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8 pEC50
Reference (Journal): Structural requirements for activation of the 5-oxo-6E,8Z, 11Z,14Z-eicosatetraenoic acid (5-oxo-ETE) receptor: identification of a mead acid metabolite with potent agonist activity.
Published in: J Pharmacol Exp Ther

Ligand: 5-oxo-20-HETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.5 pEC50
Reference (Journal): Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils.
Published in: J Immunol

Ligand: 5-oxo-15-HETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.7 pEC50
Reference (Journal): 5-Oxo-eicosanoids are potent eosinophil chemotactic factors. Functional characterization and structural requirements.
Published in: J Biol Chem

Ligand: 5-oxo-15-HETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.7 pEC50
Reference (Journal): Chemical and biological characterization of oxo-eicosatetraenoic acids.
Published in: Biochim Biophys Acta

Ligand: 5-oxo-15-HETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.7 pEC50
Reference (Journal): Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils.
Published in: J Immunol

Ligand: 5-oxo-15-HETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.7 pEC50
Reference (Journal): Stimulation of human neutrophils by 5-oxo-6,8,11,14-eicosatetraenoic acid by a mechanism independent of the leukotriene B4 receptor.
Published in: J Biol Chem

Ligand: 5-oxo-12-HETE (Metabolite)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pIC50
Reference (Journal): Biological inactivation of 5-oxo-6,8,11,14-eicosatetraenoic acid by human platelets.
Published in: Blood

Ligand: 5-(6-chloro-2-hexyl-1H-indol-1-yl)-5-oxo-valeric acid (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.4 pIC50
Reference (Journal): 5-Oxo-ETE receptor antagonists.
Published in: J Med Chem